The FDA has just approved fremanezumab (Ajovy) for the preventive treatment of episodic migraine in children and adolescents ages 6–17. This is a major step forward in giving our youngest patients access to safe, effective, and well-tolerated migraine prevention tailored to their needs. At Synergy Integrative Headache Center, we are committed to offering the most advanced and evidence-based treatments—now with even more options to help kids reclaim their energy, focus, and joy.
https://www.neurologylive.com/view/fda-approves-fremanezumab-first-anti-cgrp-preventive-therapy-pediatric-episodic-migraine
